concept

RB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2519Connections

26Hypotheses

0Analyses

50Outgoing

50Incoming

2Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	RB
Linked Hypotheses	5 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    RB["RB"]
    style RB fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    RB -->|"interacts"| Als["Als"]
    RB -.->|"inhibits"| Atherosclerosis["Atherosclerosis"]
    RB -->|"activates"| Dementia["Dementia"]
    RB -->|"activates"| Alzheimer["Alzheimer"]
    RB -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
    RB -->|"interacts"| Parkinson["Parkinson"]
    MTOR([MTOR]) -.->|"inhibits"| RB
    AMPK([AMPK]) -->|"interacts"| RB
    ABCA1([ABCA1]) -->|"interacts"| RB
    P2RY12([P2RY12]) -.->|"inhibits"| RB
    ABCG1([ABCG1]) -->|"interacts"| RB
    ALS([ALS]) -->|"interacts"| RB
    MAO([MAO]) -.->|"inhibits"| RB
    ULK1([ULK1]) -->|"interacts"| RB
    ATP([ATP]) -->|"interacts"| RB
    ACTB([ACTB]) -->|"interacts"| RB

Outgoing (446)

Target	Relation	Type	Str
Alzheimer	transports	disease	0.60
Frontotemporal Dementia	inhibits	disease	0.60
Depression	inhibits	disease	0.60
Aging	biomarker_for	disease	0.60
Glioblastoma	expressed_in	disease	0.60
Amyotrophic Lateral Sclerosis	interacts_with	disease	0.60
Aging	degrades	disease	0.60
Bipolar	activates	disease	0.60
Frontotemporal Dementia	causes	disease	0.60
Parkinson	interacts_with	disease	0.60
Autism	activates	disease	0.60
Dementia	activates	disease	0.60
Alzheimer	activates	disease	0.60
Amyotrophic Lateral Sclerosis	causes	disease	0.60
Senescence	inhibits	disease	0.60
Necroptosis	activates	disease	0.60
Depression	protects_against	disease	0.60
Anxiety	protects_against	disease	0.60
Neuropathy	causes	disease	0.60
Als	activates	disease	0.60
Dementia	regulates	disease	0.60
Ferroptosis	regulates	disease	0.60
Alzheimer	interacts_with	disease	0.60
Aging	inhibits	disease	0.60
Epilepsy	inhibits	disease	0.60
Dementia	therapeutic_target	disease	0.60
Anxiety	therapeutic_target	disease	0.60
Prion Disease	regulates	disease	0.60
Huntington	regulates	disease	0.60
Tauopathy	therapeutic_target	disease	0.60
Frontotemporal Dementia	activates	disease	0.60
Cancer	activates	disease	0.60
Neurodegeneration	activates	disease	0.60
Fibrosis	regulates	disease	0.60
Dementia	interacts_with	disease	0.60
Senescence	therapeutic_target	disease	0.60
Addiction	associated_with	disease	0.60
Amyotrophic Lateral Sclerosis	regulates	disease	0.60
Frontotemporal Dementia	regulates	disease	0.60
Frontotemporal Dementia	interacts_with	disease	0.60
Neuroinflammation	activates	disease	0.60
Amyotrophic Lateral Sclerosis	activates	disease	0.60
Parkinson	activates	disease	0.60
Prion Disease	activates	disease	0.60
Huntington	activates	disease	0.60
Neuroinflammation	inhibits	disease	0.60
Traumatic Brain Injury	interacts_with	disease	0.60
Ischemia	inhibits	disease	0.60
Aging	therapeutic_target	disease	0.60
Dementia	inhibits	disease	0.60

Incoming (2073)

Source	Relation	Type	Str
PVALB	regulates	gene	0.60
ARID1B	causes	gene	0.60
SLC17A7	associated_with	gene	0.60
GRIA2	associated_with	gene	0.60
SLC32A1	associated_with	gene	0.60
SST	associated_with	gene	0.60
NPY	associated_with	gene	0.60
SLC17A6	associated_with	gene	0.60
SNAP25	associated_with	gene	0.60
HSPG2	expressed_in	gene	0.60
TXNRD1	expressed_in	gene	0.60
DDX3X	expressed_in	gene	0.60
HSPG2	regulates	gene	0.60
GAD1	expressed_in	gene	0.60
IL23A	activates	gene	0.60
ERBB4	inhibits	gene	0.60
NRG1	inhibits	gene	0.60
TXN	interacts_with	gene	0.60
LPL	interacts_with	gene	0.60
SLC6A1	interacts_with	gene	0.60
CALM1	interacts_with	gene	0.60
GJA1	interacts_with	gene	0.60
FOS	therapeutic_target	gene	0.60
CD4	therapeutic_target	gene	0.60
GJA1	therapeutic_target	gene	0.60
P38	inhibits	gene	0.60
GNPTAB	activates	gene	0.60
SLC17A5	activates	gene	0.60
CTSD	activates	gene	0.60
GBA	activates	gene	0.60
SCARB2	activates	gene	0.60
LIPA	activates	gene	0.60
NPC1	activates	gene	0.60
SMPD1	activates	gene	0.60
NAMPT	activates	gene	0.60
NAMPT	therapeutic_target	gene	0.60
TNF	therapeutic_target	gene	0.60
CYP7B1	therapeutic_target	gene	0.60
CYP46A1	therapeutic_target	gene	0.60
GSK3B	therapeutic_target	gene	0.60
NR3C1	therapeutic_target	gene	0.60
PPARG	therapeutic_target	gene	0.60
CRH	therapeutic_target	gene	0.60
CRH	expressed_in	gene	0.60
AVP	inhibits	gene	0.60
CLOCK	inhibits	gene	0.60
P38	activates	gene	0.60
SOD1	inhibits	gene	0.60
NLGN2	inhibits	gene	0.60
MFN1	activates	gene	0.60

Targeting Hypotheses (26)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.868	als	-
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.785	-	Do β-amyloid plaques and neurofibrillary
Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ	0.738	neuroinflammation	How do B cells mechanistically orchestra
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-
AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Ne	0.670	neurodegeneration	What are the specific molecular mechanis

Vascular mural cell degeneration precedes and exacerbates pa	0.661	alzheimers	SEA-AD Single-Cell Analysis: Cell-Type V
early PD proteogenomic hubs that are both causal enough and	0.626	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Sex-Specific Microglial States in Amyloi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Genetic Aging Landscape Variants and Epi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Causal Sequence of TDP-43 Nuclear Cleara
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Biophysical Determinants Shifting FUS/TD
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	CCL2-CCR2 Axis at NMJ: Mechanism of Sele
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Non-Neuronal Transcriptional Changes Pre
Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Met	0.597	neuroinflammation	What molecular mechanisms determine whet
Parthenolide perturbs adenosine transport or metabolism upst	0.506	neuropharmacology	How does parthenolide specifically modul
REV-ERB Agonist Microglial Deactivation	0.455	chronobiology	Can circadian interventions reverse micr
Phosphatidylserine Decarboxylase (PISD) Restoration to Corre	0.342	lipidomics	Lipid metabolism dysregulation in Alzhei
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacolog	0.308	metabolomics	Metabolomic signatures of neurodegenerat
Compensatory RBP Expression Therapy	0.000	-	RNA binding protein dysregulation across
Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotecti	0.000	-	Mitochondrial transfer between astrocyte
Proteostasis Network Activation for RBPs	0.000	-	RNA binding protein dysregulation across

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
IL-10 deficiency and VLC ceramide accumulation in inflammatory bowel d	validation	inflammatory bowel disease	0.900	0.00	IL-10 knockout mice	proposed	N/A
Irisin effects on angiogenesis in human endothelial cells	exploratory	bone fracture	0.900	0.00	human umbilical vein endotheli	proposed	N/A

Related Papers (8)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990]	Keller A	Annual review of physiology	2026
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811]	Wang Y, Zhang Z, Cao L, Huang S, Huang X	J Ethnopharmacol	2026
Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710]	Yang X, Xiao JH, Li X, Liu RM, Yuan Q	J Ethnopharmacol	2026
Novel insights into meningioma brain invasion with spatial transcriptomic profil [PMID:41486296]	Maier AD, Laurentiussen CO, Michaelsen S	Acta Neuropathol Commun	2026
Brain vascular stability relies on PAK2-cilia-PDGF-BB-HSPGs on basolateral side [PMID:41490797]	Prabhudesai S, Thirugnanam K, Song X, Ya	Life Sci Alliance	2026
Plasma platelet-derived growth factor receptor-β decrease correlates with blood- [PMID:41530860]	Li J, Li A, Ye C, Zhang L, Jiang M et al	Mol Neurodegener	2026
FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis [PMID:41680210]	Sun F, Zhao Y, Do J, Cheng P, Li E et al	Nat Commun	2026
Loss of Pericyte Exacerbates Alzheimer's Disease-Associated Retinal Pathology. [PMID:41814129]	Hai-Chao C, Fu-Lin G, Jia-Xin C, Yi-Shu	Clinical & experimental ophtha	2026

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning RB in their description or question text

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.661 · alzheimers · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

early PD proteogenomic hubs that are both causal enough and accessible enough to

Score: 0.626 · neurodegeneration · 2026-04-28

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro